

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6133037

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the SPELLING OF DR. FELIX CLEEMAN AND ROMY REIMAN previously recorded on Reel 050255 Frame 0026. Assignor(s) hereby confirms the CORRECT SPELLING IS DR. FELIX CLEEMANN AND ROMY REIMANN.
CONVEYING PARTY DATA	
Name	Execution Date
DR. NICOLA BISEK	04/29/2019
DR. HARALD RAU	04/23/2019
DR. FELIX CLEEMANN	04/29/2019
DR. THOMAS KNAPPE	04/24/2019
ROMY REIMANN	05/03/2019
RECEIVING PARTY DATA	
Name:	ASCENDIS PHARMA GMBH
Street Address:	IM NEUENHEIMER FELD 584
City:	HEIDELBERG
State/Country:	GERMANY
Postal Code:	69120
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15502084
CORRESPONDENCE DATA	
Fax Number:	(212)588-0500
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	212-588-0800
Email:	docketing@haugpartners.com, smccaskey@haugpartners.com
Correspondent Name:	HAUG PARTNERS LLP
Address Line 1:	745 FIFTH AVENUE
Address Line 2:	10TH FLOOR
Address Line 4:	NEW YORK, NEW YORK 10151
ATTORNEY DOCKET NUMBER:	514453-4004
NAME OF SUBMITTER:	HOWARD NG
SIGNATURE:	/Howard Ng/
DATE SIGNED:	06/02/2020

PATENT

Total Attachments: 9

source=CPX69245PCUS_initialed corrected assignment (01989424)#page1.tif
source=CPX69245PCUS_initialed corrected assignment (01989424)#page2.tif
source=CPX69245PCUS_initialed corrected assignment (01989424)#page3.tif
source=CPX69245PCUS_initialed corrected assignment (01989424)#page4.tif
source=CPX69245PCUS_initialed corrected assignment (01989424)#page5.tif
source=CPX69245PCUS_initialed corrected assignment (01989424)#page6.tif
source=CPX69245PCUS_initialed corrected assignment (01989424)#page7.tif
source=CPX69245PCUS_initialed corrected assignment (01989424)#page8.tif
source=CPX69245PCUS_initialed corrected assignment (01989424)#page9.tif

ASSIGNMENT


WHEREAS, the undersigned Inventor(s) (hereinafter referred to as Assignor) has invented the invention described in the patent application entitled **Prodrugs Comprising an Aminoalkyl Glycine Linker** that was filed in the United States Patent and Trademark Office on February 6, 2017, and was assigned application serial no. 15/502,084, and is/are the owner(s) of the same and any and all United States Letters Patent to be obtained therefrom (hereinafter referred to as Invention);

AND WHEREAS, **Ascendis Pharma GmbH**, having an address of Im Neuenheimer Feld 584, 69120 Heidelberg, Germany (hereinafter referred to as Assignee) is desirous of acquiring the entire right, title, and interest in and to said Invention;

NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, transfer, and set over unto said Assignee, and Assignor's legal representatives, successors, and assigns, the entire right, title, and interest in and to said Invention, including any continuations, continuations-in-part, divisions, reissues, re-examinations, or extensions thereof, including any and all patents of the United States and foreign countries that may be issued for said Invention;

UPON SAID CONSIDERATIONS, Assignor hereby agrees with Assignee that Assignor will not execute any writing or do any act whatsoever conflicting with these presents;


FURTHERMORE, Assignor covenants that Assignor will, at any time upon Assignee's request, without further or additional consideration but at the expense of said Assignee, execute such additional assignments and other writings and do such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and will render all necessary assistance in making application for and obtaining original, divisional, continuation, continuation-in-part, reexamined, reissued, or extended Letters Patent of the United States or of any and all foreign countries on said Invention, and in enforcing any rights or causes of action accruing as a result of such applications or patents, including giving testimony in any proceedings or transactions involving such applications or patents, and executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind and inure to the benefit of the assignor and legal representatives of Assignor and Assignee.



Dr. Nicola Bisck

Inventor

Date: 29-Apr-2019



Signature of Witness

Guillaume MAITRE

Printed Name of Witness


Date: 29-Apr-2019



Dr. Harald Rau

Inventor

Date: 23.4.19




Signature of Witness

ROXANA LEMNARU

Printed Name of Witness


Date: 23.04.19



Dr. Felix Gleeman - Gleemann

Inventor

Date: 29.04.19



Signature of Witness

MAX BLAZELAK

Printed Name of Witness

Date: 29.04.19

T. Knappe

Dr. Thomas Knappe

Inventor

Date: 24/4/2019

[Signature]
Signature of Witness

ROXANA LEMNARU

Printed Name of Witness

Date: 24-04-2019

R. Reiman

Romy Reiman — Reimann

Inventor

Date: 03-May-2019

[Signature]

Signature of Witness

Sebastian Schlitt

Printed Name of Witness

Date: 03-May-2019

[Signature]
[Assignee Representative Name]

[Assignee Representative Title]

Ascendis Pharma GmbH

Date: 08 MAY 2019

[Signature]

Signature of Witness

ROXANA LEMNARU

Printed Name of Witness

Date: 08-MAY-2019

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5539850

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DR. NICOLA BISEK	04/29/2019
DR. HARALD RAU	04/23/2019
DR. FELIX CLEEMAN	04/29/2019
DR. THOMAS KNAPPE	04/24/2019
ROMY REIMAN	05/03/2019
RECEIVING PARTY DATA	
Name:	ASCENDIS PHARMA GMBH
Street Address:	IM NEUENHEIMER FELD 584
City:	HEIDELBERG
State/Country:	GERMANY
Postal Code:	69120
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15502084
CORRESPONDENCE DATA	
Fax Number:	(212)588-0500
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	212-588-0800
Email:	docket@haugpartners.com, smccaskey@haugpartners.com
Correspondent Name:	HAUG PARTNERS LLP
Address Line 1:	745 FIFTH AVENUE
Address Line 2:	10TH FLOOR
Address Line 4:	NEW YORK, NEW YORK 10151
ATTORNEY DOCKET NUMBER:	514453-4004
NAME OF SUBMITTER:	JOSEPH W. TRELOAR
SIGNATURE:	/Joseph W. Treloar/
DATE SIGNED:	05/24/2019
Total Attachments: 3	



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

SEPTEMBER 5, 2019

PTAS

HAUG PARTNERS LLP
745 FIFTH AVENUE
10TH FLOOR
NEW YORK, NY 10151

505493046

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 05/24/2019

REEL/FRAME: 050255/0026
NUMBER OF PAGES: 5

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 514453-4004

ASSIGNOR:

BISEK, NICOLA, DR.

DOC DATE: 04/29/2019

ASSIGNOR:

RAU, HARALD, DR.

DOC DATE: 04/23/2019

ASSIGNOR:

CLEEMAN, FELIX, DR. Last name should be
spelled CLEEMANN

DOC DATE: 04/29/2019

ASSIGNOR:

KNAPPE, THOMAS, DR.

DOC DATE: 04/24/2019

ASSIGNOR:

REIMAN, ROMY Last name should be
spelled REIMANN

DOC DATE: 05/03/2019

ASSIGNEE:

ASCENDIS PHARMA GMBH
IM NEUENHEIMER FELD 584
HEIDELBERG, GERMANY 69120

APPLICATION NUMBER: 15502084

FILING DATE: 02/06/2017

PATENT NUMBER:

ISSUE DATE:

TITLE: PRODRUGS COMPRISING AN AMINOALKYL GLYCINE LINKER

ASSIGNMENT RECORDATION BRANCH

PUBLIC RECORDS DIVISION

ASSIGNMENT


WHEREAS, the undersigned Inventor(s) (hereinafter referred to as Assignor) has invented the invention described in the patent application entitled **Prodrugs Comprising an Aminoalkyl Glycine Linker** that was filed in the United States Patent and Trademark Office on **February 6, 2017**, and was assigned application serial no. **15/502,084**, and is/are the owner(s) of the same and any and all United States Letters Patent to be obtained therefrom (hereinafter referred to as Invention);

AND WHEREAS, **Ascendis Pharma GmbH**, having an address of Im Neuenheimer Feld 584, 69120 Heidelberg, Germany (hereinafter referred to as Assignee) is desirous of acquiring the entire right, title, and interest in and to said Invention;

NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, transfer, and set over unto said Assignee, and Assignor's legal representatives, successors, and assigns, the entire right, title, and interest in and to said Invention, including any continuations, continuations-in-part, divisions, reissues, re-examinations, or extensions thereof, including any and all patents of the United States and foreign countries that may be issued for said Invention;

UPON SAID CONSIDERATIONS, Assignor hereby agrees with Assignee that Assignor will not execute any writing or do any act whatsoever conflicting with these presents;


FURTHERMORE, Assignor covenants that Assignor will, at any time upon Assignee's request, without further or additional consideration but at the expense of said Assignee, execute such additional assignments and other writings and do such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and will render all necessary assistance in making application for and obtaining original, divisional, continuation, continuation-in-part, reexamined, reissued, or extended Letters Patent of the United States or of any and all foreign countries on said Invention, and in enforcing any rights or causes of action accruing as a result of such applications or patents, including giving testimony in any proceedings or transactions involving such applications or patents, and executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of Assignor and Assignee.



Dr. Nicola Bisek

Inventor

Date: 29-Apr-2019




Signature of Witness

Guillaume MAITRE

Printed Name of Witness

Date: 29-Apr-2019



Dr. Harald Rau

Inventor

Date: 23.4.19




Signature of Witness

ROXANA LEMNARU

Printed Name of Witness

Date: 23.04.19



Dr. Felix Cleeman

Inventor

Date: 29.04.19



Signature of Witness

MAX BLAZEJAK

Printed Name of Witness

Date: 29.04.19

Dr. Thomas Knappe

Dr. Thomas Knappe

Inventor

Date: 24/4/2019

Signature of Witness

Roxana Lemnar
.....
ROXANA LEMNARU

Printed Name of Witness

Date: 24-04-2019

Romy Reiman

Romy Reiman

Inventor

Date: 03-May-2019

Signature of Witness

Sebastian Schlitt
.....
Sebastian Schlitt

Printed Name of Witness

Date: 03-May-2019

Jutta Sandberg
.....
[Assignee Representative Name]

[Assignee Representative Title]

Ascendis Pharma GmbH

Date: 08 MAY 2019

Roxana Lemnar
.....
Signature of Witness

ROXANA LEMNARU

Printed Name of Witness

Date: 08 - MAY - 2019